Yihui

Yihui Pharmaceuticals is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the discovery and development of novel small molecule therapeutics targeting deubiquitinating enzymes (DUBs). The company's primary focus is on oncology, with a lead program, YH-201, which acts as a potent and selective inhibitor of Ubiquitin-specific protease 7 (USP7). By modulating the protein degradation pathway, Yihui aims to provide innovative treatments for various solid tumors and hematological malignancies. The company leverages its proprietary medicinal chemistry platform to advance a pipeline of candidates through early-stage clinical trials. Its research efforts are supported by prominent venture capital firms, positioning it as a key player in the emerging field of DUB-targeted therapies. Yihui is currently evaluating its lead candidate in Phase 1 clinical trials to establish safety and preliminary efficacy in patients with advanced cancers.